Tumor endothelial markers: New targets for cancer therapy

Current Opinion in Oncology

Volumn 16, Issue 1, 2004, Pages 44-49

  Nanda, Akash ^a   St Croix, Brad ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Gene expression; Tumor endothelial markers (TEMs)

Indexed keywords

ANTHRAX TOXIN RECEPTOR; BEVACIZUMAB; IMMUNOTOXIN; MOLECULAR MARKER; RECEPTOR; TUMOR ENDOTHELIUM MARKER 1; TUMOR ENDOTHELIUM MARKER 5; TUMOR ENDOTHELIUM MARKER 7; TUMOR ENDOTHELIUM MARKER 8; TUMOR MARKER; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; CANCER SURVIVAL; CANCER THERAPY; CELL FRACTIONATION; CELL SURFACE; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM; ENDOTHELIUM CELL; GENOME ANALYSIS; GENOMICS; HUMAN; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS; SIDE EFFECT; STRUCTURE ANALYSIS; SURVIVAL TIME; TUMOR; TUMOR CELL; TUMOR MODEL; TUMOR VASCULARIZATION; VALIDATION PROCESS; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ENDOTHELIAL CELLS; GENOMICS; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 2442620564     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200401000-00009     Document Type: Review

References (59)

1. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739. Excellent review on the status of anti-angiogenic agents in the clinic and what these studies have taught us.
2. Lyden D, Hattori K, Dias S, et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201.
3. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
4. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4-6.
5. Brekken RA, Overholser JP, Stastny VA, et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60:5117-5124.
6. Grunstein J, Roberts WG, Mathieu-Costello O, et al.: Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999, 59:1592-1598.
7. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676. Great review of the role of VEGF and its receptors in angiogenesis as well as of the current status of clinical trials that target VEGF.
8. Viloria-Petit A, Miquerol L, Yu JL, et al.: Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 2003, 22:4091-4102. This important paper is the first to provide good evidence for the existence of VEGF-independent tumors.
9. Inoue M, Hager JH, Ferrara N, et al.: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1:193-202. Supports a central role for VEGF in tumor angiogenesis occurring in the RIP1-Tag2 mouse model of pancreatic islet carcinoma.
10. Lyden D, Young AZ, Zagzag D, et al.: Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401:670-677.
11. Itoh T, Tanioka M, Yoshida H, et al.: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998, 58:1048-1051.
12. Ishida T, Kundu RK, Yang E, et al.: Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo. J Biol Chem 2003, 278:34598-34604.
13. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13:31-36.
14. McCarthy M: Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003, 361:1959.
15. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
16. Miller KD: E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003, 3:421-422.
17. Trail PA, King HD, Dubowchik GM: Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003, 52:328-337.
18. Garber K: Angiogenesis inhibitors suffer new setback. Nat Biotechnol 2002, 20:1067-1068.
19. Huang J, Frischer JS, Serur A, et al.: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003, 100:7785-7790. Demonstrates potent antitumor activity using a receptor-mediated VEGF trap.
20. Kerbel RS: Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001, 19:45S-51S.
21. Seon BK, Matsuno F, Haruta Y, et al.: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997, 3:1031-1044.
22. Matsuno F, Haruta Y, Kondo M, et al.: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999, 5:371-382.
23. Halin C, Rondini S, Nilsson F, et al.: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002, 20:264-269.
24. Borsi L, Balza E, Carnemolla B, et al.: Selective targeted delivery of TNFα to tumor blood vessels. Blood 2003 [Epub ahead of print].
25. Arora N, Masood R, Zheng T, et al.: Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999, 59:183-188.
26. Wild R, Dhanabal M, Olson TA, Ramakrishnan S: Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. Br J Cancer 2000, 83:1077-1083.
27. Ran S, Gao B, Duffy S, et al.: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998, 58:4646-4653.
28. Huang X, Molema G, King S, et al.: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997, 275:547-550.
29. Nilsson F, Kosmehl H, Zardi L, Neri D: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001, 61:711-716.
30. Hu P, Yan J, Sharifi J, et al.: Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res 2003, 63:5046-5053. First study to compare the effectiveness of different tissue-factor fusion proteins.
31. Hood JD, Bednarski M, Frausto R, et al.: Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
32. Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD 105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 1996, 39:239-242.
33. Balza E, Castellani P, Zijlstra A, et al.: Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001, 94:579-585.
34. Witmer AN, Dai J, Weich HA, et al.: Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 2002, 50:767-777.
35. Langley RR, Russell J, Eppihimer MJ, et al.: Quantification of murine endothelial cell adhesion molecules in solid tumors. Am J Physiol 1999, 277:H1156-H1166.
36. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684. Good review on hypoxia-regulated genes such as VEGF and their role in angiogenesis.
37. Bergers G: Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410. Excellent overview of the phenotypic differences between normal physiological angiogenesis and tumor angiogenesis.
38. Santimaria M, Moscatelli G, Viale GL, et al.: Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003, 9:571-579. Demonstrates that an antibody against the ED-B domain of fibronectin can target primary tumors and metastatic lesions in cancer patients.
39. Ruoslahti E: Specialization of tumour vasculature. Nat Rev Cancer 2002, 2:83-90.
40. Ditzel HJ: Human antibodies in cancer and autoimmune disease. Immunol Res 2000, 21:185-193.
41. Crameri R, Achatz G, Weichel M, Rhyner C: Direct selection of cDNAs by phage display. Methods Mol Biol 2002, 185:461-469.
42. Pasqualini R, Koivunen E, Kain R, et al.: Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000, 60:722-727.
43. St Croix B, Rago C, Velculescu V, et al.: Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
44. Carson-Walter EB, Watkins DN, Nanda A, et al.: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001, 61:6649-6655.
45. Opavsky R, Haviernik P, Jurkovicova D, et al.: Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem 2001, 276:38795-38807.
46. Rettig WJ, Garin-Chesa P, Healey JH, et al.: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A 1992, 89:10832-10836.
47. Christian S, Ahorn H, Koehler A, et al.: Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001, 276:7408-7414.
48. Weiler H, Isermann BH: Thrombomodulin. J Thromb Haemost 2003, 1:1515-1524.
49. Im DS: Orphan G protein-coupled receptors and beyond. Jpn J Pharmacol 2002, 90:101-106.
50. Stacey M, Lin HH, Gordon S, McKnight AJ: LNB-TM7, a group of seven-transmembrane proteins related to family-B G-protein-coupled receptors. Trends Biochem Sci 2000, 25:284-289.
51. Qi LJ, Leung AT, Xiong Y, et al.: Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry (Mosc) 1997, 36:12442-12448.
52. Bradley KA, Mogridge J, Mourez M, et al.: Identification of the cellular receptor for anthrax toxin. Nature 2001, 414:225-229.
53. Scobie HM, Rainey GJ, Bradley KA, Young JA: Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A 2003, 100:5170-5174. This important paper establishes that CMG2, the closest TEM8 homologue, is a second receptor for anthrax toxin.
54. Bradley KA, Young JA: Anthrax toxin receptor proteins. Biochem Pharmacol 2003, 65:309-314.
55. Duesbery NS, Resau J, Webb CP, et al.: Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 2001, 98:4089-4094.
56. Koo HM, VanBrocklin M, McWilliams MJ, et al.: Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase. Proc Natl Acad Sci U S A 2002, 99:3052-3057.
57. Liu S, Aaronson H, Mitola DJ, et al.: Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A 2003, 100:657-662. This important study demonstrates that the therapeutic window for treating tumors with anthrax toxin can be increased by incorporating a urokinase piasminogen activator cleavage site into the protective antigen sequence.
58. McDonald DM, Choyke PL: Imaging of angiogenesis: from microscope to clinic. Nat Med 2003, 9:713-725. Excellent overview of some of the latest technologies available for imaging angiogenesis.
59. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002, 94:883-893. Important review highlighting the limitations of using microvessel density as a prognostic indicator.